Addition of glucose to an oral fat load reduces postprandial free fatty acids and prevents the postprandial increase in complement component

American Journal of Clinical Nutrition

Volumn 79, Issue 3, 2004, Pages 510-515

  Van Oostrom, Antoine J ^a   Van Dijk, Hans ^b   Verseyden, Caroline ^a   Sniderman, Allan D ^c   Cianflone, Katherine ^c   Rabelink, Ton J ^a   Cabezas, Manuel Castro ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Acylation stimulating protein; Complement component 3; Free fatty acids; Healthy men; Insulin; Triacylglycerol

Indexed keywords

ACYLATION STIMULATING PROTEIN; COMPLEMENT COMPONENT C3; FATTY ACID; INSULIN; COMPLEMENT C3A, DES ARG (77); COMPLEMENT C3A, DES-ARG-(77); COMPLEMENT COMPONENT C3A; DRUG DERIVATIVE; GLUCOSE; KETONE BODY; PLASMA PROTEIN; TRIACYLGLYCEROL; VOLATILE FATTY ACID;

ADULT; ARTICLE; CONTROLLED STUDY; DIET; FAT INTAKE; FATTY ACID BLOOD LEVEL; GLUCOSE INTAKE; HUMAN; HUMAN EXPERIMENT; INGESTION; INSULIN RESPONSE; MALE; NORMAL HUMAN; TRIACYLGLYCEROL BLOOD LEVEL; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DIET RESTRICTION; INSULIN RESISTANCE; METABOLISM; OBESITY; PHYSIOLOGY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; BLOOD PROTEINS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C3A; CROSS-OVER STUDIES; DIETARY FATS; FASTING; FATTY ACIDS, VOLATILE; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; KETONE BODIES; MALE; OBESITY; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 1642341251     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/79.3.510     Document Type: Article

References (30)

1. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-66.
2. Figueredo A, Ibarra JL, Bagazgoitia J, et al. Plasma C3d levels and ischemic heart disease in type II diabetes. Diabetes Care 1993;16:445-9.
3. Muscari A, Massarelli G, Bastagli L, et al. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Heart J 2000;21:1081-90.
4. Muscari A, Massarelli G, Bastagli L, et al. Relationship between serum C3 levels and traditional risk factors for myocardial infarction. Acta Cardiol 1998;53:345-54.
5. Weyer C, Tataranni PA, Pratley RE. Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 2000;23:779-85.
6. Ylitalo K, Pajukanta P, Men S, et al. Serum C3 but not plasma acylation-stimulating protein is elevated in Finnish patients with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2001;21:838-43.
7. Halkes CJM, van Dijk H, de Jaegere PP, et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol 2001;21:1526-30.
8. Barnum SR, Volanakis JE. Structure and function of C3. Year Immunol 1989;6:208-28.
9. Scantlebury T, Sniderman AD, Cianflone K. Regulation by retinoic acid of acylation-stimulating protein and complement C3 in human adipocytes. Biochem Genet 2001;356:445-52.
10. Cianflone KM, Sniderman AD, Walsh MJ, Vu HT, Gagnon J, Rodriguez MA. Purification and characterization of acylation stimulating protein. J Biol Chem 1989;264:426-30.
11. Cianflone K, Maslowska M, Sniderman AD. Acylation stimulating protein (ASP), an adipocyte autocrine: new directions. Semin Cell Dev Biol 1999;10:31-41.
12. Van Harmelen V, Reynisdottir S, Cianflone K, et al. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem 1999;274:18243-51.
13. Germinario R, Sniderman AD, Manuel S, Lefebvre SP, Baldo A, Cianflone K. Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. Metabolism 1993;42:574-80.
14. Sniderman AD, Maslowska M, Cianflone K. Of mice and men (and women) and the acylation-stimulating protein pathway. Curr Opin Lipidol 2000;11:291-6.
15. Sniderman AD, Cianflone K, Arner P, Summers LK, Frayn KN. The adipocyte, fatty acid trapping, and atherogenesis. Arterioscler Thromb Vasc Biol 1998;18:147-51.
16. Frayn KN. Non-esterified fatty acid metabolism and postprandial lipaemia. Atherosclerosis 1998;141(suppl):S41-6.
17. Charlesworth JA, Peake PW, Campbell LV, Pussell BA, O'Grady S, Tzilopoulos T. The influence of oral lipid loads on acylation stimulating protein (ASP) in healthy volunteers. Int J Obes Relat Metab Disord 1998;22:1096-102.
18. Koistinen HA, Vidal H, Karonen SL, et al. Plasma acylation stimulating protein concentration and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men. Arterioscler Thromb Vasc Biol 2001;21:1034-9.
19. Meijssen S, van Dijk H, Verseyden C, Erkelens DW, Castro Cabezas M. Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2002;22:811-6.
20. Krebs M, Stingl H, Nowotny P, et al. Prevention of in vitro lipolysis by tetrahydrolipstatin. Clin Chem 2000;46:950-4.
21. Meijssen S, Castro Cabezas M, Twickler TB, Jansen H, Erkelens DW. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. J Lipid Res 2000;41:1096-102.
22. Saleh J, Summers LK, Cianflone K, Fielding BA, Sniderman AD, Frayn KN. Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. J Lipid Res 1998;39:884-91.
23. Meijssen S, Castro Cabezas M, Ballieux CG, Derksen RJ, Bilecen S, Erkelens DW. Insulin mediated inhibition of hormone sensitive lipase activity in vivo in relation to endogenous catecholamines in healthy subjects. J Clin Endocrinol Metab 2001;86:4193-7.
24. de Bruin TW, Vos MC, Kortlandt W, Bouma BN, Erkelens DW. Proteolysis of human apolipoprotein B: effect on quantitative immunoturbidimetry. Clin Chim Acta 1990;193:137-45.
25. Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 1992;267:12736-41.
26. Weyer C, Pratley RE. Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese Pima Indians compared to Caucasians. Obes Res 1999;7:444-52.
27. Cohen JC, Berger GM. Effects of glucose ingestion on postprandial lipemia and triglyceride clearance in humans. J Lipid Res 1990;31:597-602.
28. Keller U, Lustenberger M, Muller-Brand J, Gerber PP, Stauffacher W. Human ketone body production and utilization studied using tracer techniques: regulation by free fatty acids, insulin, catecholamines, and thyroid hormones. Diabetes Metab Rev 1989;5:285-98.
29. Ebeling P, Teppo AM, Koistinen HA, Koivisto VA. Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes. Metabolism 2001;50:283-7.
30. Ozata M, Gungor D, Turan M, et al. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects. J Clin Endocrinol Metab 2001;86:3659-64.